Deciphering the lung microbiota in COVID-19 patients: insights from culture analysis, FilmArray pneumonia panel, ventilation impact, and mortality trends.

Publication date: Dec 03, 2024

Few studies have analyzed the role of the lung microbiome in the diagnosis of pulmonary coinfection in ventilated ICU COVID-19 patients. We characterized the lung microbiota in COVID-19 patients with severe pneumonia on invasive mechanical ventilation using full-length 16S rRNA gene sequencing and established its relationship with coinfections, mortality, and the need for mechanical ventilation for more than 7 days. This study included 67 COVID-19 ICU patients. DNA extracted from mini-bronchoalveolar lavage fluid and endotracheal aspirates was amplified by PCR with specific 16S primers (27F and 1492R). General and relative bacterial abundance analysis was also conducted. Alpha diversity was measured by the Shannon and Simpson indices, and differences in the microbiota were established using beta diversity. A linear discriminant analysis (LDA) effect size algorithm was implemented to describe biomarkers. Streptococcus spp. represented 51% of the overall microbial abundance. There were no differences in alpha diversity between the analyzed variables. There was variation in bacterial composition between samples that had positive and negative cultures. The genera Veillonella sp. , Granulicatella sp. , Enterococcus sp. and Lactiplantibacillus sp. , with LDA scores > 2, were biomarkers associated with negative cultures. Rothia sp. , with an LDA score > 2, was a biomarker associated with mortality.

Open Access PDF

Concepts Keywords
7days Aged
Biomarkers Bacteria
Filmarray Bronchoalveolar Lavage Fluid
Lactiplantibacillus Coinfection
Pneumonia COVID-19
Female
Humans
Intensive Care Units
Lung
Male
Microbiota
Middle Aged
Respiration, Artificial
RNA, Ribosomal, 16S
RNA, Ribosomal, 16S
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease MESH pneumonia
disease IDO role
disease MESH coinfection
disease IDO algorithm
disease MESH Acute respiratory distress syndrome
disease IDO deoxyribonucleic acid
drug DRUGBANK Coenzyme M
disease MESH lung injury
disease MESH inflammation
disease MESH dysbiosis
disease MESH critical illness
disease MESH superinfection
disease MESH community acquired infection
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Hypertension
disease MESH Neoplasia
disease MESH Heart failure
disease MESH Cirrhosis
disease MESH Pulmonary embolism
drug DRUGBANK Dexamethasone
drug DRUGBANK Methylprednisolone
drug DRUGBANK Tocilizumab
drug DRUGBANK Ceftriaxone
drug DRUGBANK Cefepime
drug DRUGBANK Ampicillin
drug DRUGBANK Sulbactam
disease IDO immunodeficiency
drug DRUGBANK Dimercaprol
disease IDO host
disease IDO commensal
disease IDO bacteria
disease MESH infection
disease IDO symptom
drug DRUGBANK Isopropyl Alcohol
drug DRUGBANK Water
disease IDO reagent
disease IDO assay
drug DRUGBANK Albendazole
drug DRUGBANK (S)-Des-Me-Ampa
pathway REACTOME Reproduction

Original Article

(Visited 2 times, 1 visits today)